SCHEMBL26113643

SCHEMBL26113643

COc1cc(N)c(C)c(OC)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.44
ALDH1A1 P00352 6/20 0.43
CYP3A4 P08684 4/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 3/20 0.41
TDP1 Q9NUW8 2/20 0.40
POLB P06746 2/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TUBB4A P04350 2/20 0.40
TUBB P07437 2/20 0.40
TUBA3C P0DPH7 2/20 0.40
TUBA1B P68363 2/20 0.40
TUBA4A P68366 2/20 0.40
TUBB4B P68371 2/20 0.40
TUBB3 Q13509 2/20 0.40
TUBB2A Q13885 2/20 0.40
TUBB8 Q3ZCM7 2/20 0.40
TUBA3E Q6PEY2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30594536 1.00 ACHE (0.44) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL8465680 0.86 ACHE (0.50) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL11307252 0.86 ALDH1A1 (0.46) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL10621551 0.84 ACHE (0.43) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL30949884 0.84 ACHE (0.46) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL25952537 0.83 ACHE (0.55) ACHEALDH1A1CYP3A4TDP1POLB
SCHEMBL25386240 0.81 POLB (0.45) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL6927970 0.81 CYP3A4 (0.43) ACHEALDH1A1CYP3A4NPC1GAA
SCHEMBL29568447 0.79 CYP3A4 (0.40) ACHEALDH1A1CYP3A4GAATDP1
SCHEMBL3010210 0.79 CYP3A4 (0.40) ACHEALDH1A1CYP3A4GAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4482579-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO INC (US) 2026-02-18 EP disclosed
US-12428375-B2 Compounds and compositions for treating conditions associated with LPA receptor activity LHOTSE BIO, INC. (US) 2025-09-30 US disclosed
US-20240376054-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2024-11-14 US disclosed
US-11884627-B2 Compounds and compositions for treating conditions associated with LPA receptor activity LHOTSE BIO, INC. (US) 2024-01-30 US disclosed
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2023-10-12 US disclosed
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322675-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR2, LPAR1, LPAR6 ACHE 1754/4885ALDH1A1 1863/4885CYP3A4 4716/4885
US-11884627-B2 Compounds and compositions for treating conditions associated with LPA receptor activity LPAR2, LPAR1, LPAR6 ACHE 1754/4885ALDH1A1 1863/4885CYP3A4 4716/4885
US-20240376054-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR2, LPAR1, LPAR6 ACHE 1754/4885ALDH1A1 1863/4885CYP3A4 4716/4885
US-12428375-B2 Compounds and compositions for treating conditions associated with LPA receptor activity LPAR2, LPAR1, LPAR6 ACHE 1754/4885ALDH1A1 1863/4885CYP3A4 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.